📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-01 16:14
690 analysed today
690
Today
133,579
All-time analysed
40,122
Positive
6,284
Negative
79,354
Neutral
7,751
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
44 announcements match the current filters (relevance ≥ 5).
Gujarat Themis Biosyn approves Rs 335 Cr preferential issue at Rs 408 per share
The Board of Directors of Gujarat Themis Biosyn has approved a preferential equity issue to raise up to Rs 335.00 crore. The company will issue up to 82,10,786 fully paid-up equity shares of face value Re 1 each at an issue price of Rs 408 per share (including Rs 407 premium). Promoter entity Pharmaceutical Business Group (India) Limited will subscribe to Rs 250.00 crore (61,27,453 shares), while marquee non-promoter investors including Dr. Yusuf Khwaja Hamied and institutional funds will invest the remaining Rs 85.00 crore.
Confidence: HIGH
What changedThe board approved a major capital raise of Rs 335 crore via preferential allotment to promoter and select non-promoter institutional/HNI investors.
Why it mattersA fundraise of Rs 335 crore is massive relative to recent quarterly revenue (Rs 43.79 Cr in Q1 FY27), providing substantial growth capital for the company's ongoing fermentation capacity doubling and API forward integration.
Total Fundraise Amount: Rs 335,00,00,688Shares to be Issued: 82,10,786Issue Price per Share: Rs 408Promoter Contribution: Rs 250,00,00,824Non-promoter Contribution: Rs 85,00,00,864
📅 Short termPositive sentiment driven by strong promoter backing (Rs 250 Cr) and participation from marquee pharmaceutical investors like Dr. Yusuf Khwaja Hamied.
📈 Long termStrengthens the balance sheet significantly, providing abundant liquidity to fund capacity expansion from 216 MT to 432 MT and support API launches.
⚠ Risk flags
- Equity dilution of existing minority shareholders
- Shareholder and regulatory approvals pending
Key Highlights
Approved preferential issue of up to 82,10,786 equity shares at Rs 408 per share, raising up to Rs 335.00 crore
Promoter entity Pharmaceutical Business Group (India) Ltd to invest Rs 250.00 crore (61,27,453 shares)
Non-promoter investors include Yusuf Khwaja Hamied (Rs 10.00 cr) and Special Situation/ISAF funds (Rs 75.00 cr)
Issue price of Rs 408 is near the current market price of Rs 422.10, subject to shareholder and regulatory approvals
👀 What to Watch
Track shareholder approval via upcoming postal ballot/EGM and subsequent stock exchange in-principle approvals, as well as management disclosures regarding capex and utilization of proceeds.
Gujarat Themis Biosyn raises ₹750 Cr via QIP at ₹354/share; allots 2.12 Cr shares
Gujarat Themis Biosyn Limited has successfully concluded its Qualified Institutions Placement (QIP), raising ₹749.99 crore. The Fund-Raising Committee approved the allotment of 2,11,86,440 equity shares of face value ₹1 each at an issue price of ₹354 per share (including a 4.98% discount to the floor price). This expands the total paid-up equity share capital by 19.44% to 13,01,51,705 shares. Key institutional participants include Quant Mutual Fund, Kotak Mahindra Life Insurance, Ayushmat Ltd, and Capri Global Capital.
Confidence: HIGH
What changedThe company completed a ₹750 crore QIP fundraise, expanding its equity base from 10.89 crore shares to 13.01 crore shares.
Why it mattersThe ₹750 crore fundraise significantly strengthens the balance sheet (representing more than 4x its annualized revenue run-rate of ~₹175 crore), providing substantial growth capital for upcoming fermentation and API capacity expansions.
Total fundraise amount: ₹749.99 crIssue price per share: ₹354Shares allotted: 2,11,86,440Post-issue equity shares: 13,01,51,705Equity dilution (post-issue base): 16.28%
📅 Short termThe successful closure of the QIP with reputed domestic institutional investors (DIIs) is positive, though short-term market adjustments may reflect the ₹354 issue price and 16.28% equity dilution.
📈 Long termProvides strong capital backing to fund ongoing capex in high-value APIs and fermentation capacity doubling (from 216 MT to 432 MT), driving structural growth.
⚠ Risk flags
- Equity dilution of ~16.28% on post-issue capital base
- Execution risk in deploying large capital effectively
Key Highlights
Allotted 2,11,86,440 equity shares at an issue price of ₹354 per share, raising ₹749.99 crore
Issue price of ₹354 includes a discount of ₹18.57 per share (4.98%) to the SEBI floor price
Paid-up share capital increased from ₹10.89 crore (10.89 crore shares) to ₹13.01 crore (13.01 crore shares)
Quant Small Cap Fund allocated 25.67% and Kotak Mahindra Life Insurance allocated 13.33% of the issue
👀 What to Watch
Track subsequent company disclosures regarding the specific deployment schedule of the ₹750 Cr proceeds toward fermentation capacity expansion and API integration, alongside post-issue shareholding pattern changes.
Gujarat Themis Closes ~Rs 750 Cr QIP at Rs 354/Share (4.98% Discount)
Gujarat Themis Biosyn Limited has concluded its Qualified Institutions Placement (QIP) on August 28, 2026. The Fund-Raising Committee approved the allotment of 2,11,86,440 equity shares of face value Rs 1 each at an issue price of Rs 354 per share (including a premium of Rs 353 per share). The issue price reflects a 4.98% discount (Rs 18.57 per share) to the SEBI floor price of Rs 372.57. Total capital raised from institutional buyers amounts to approximately Rs 750 crore.
Confidence: HIGH
What changedThe company has finalized its QIP issue price and share allocation, successfully closing the fundraise opened on August 25, 2026.
Why it mattersThe ~Rs 750 crore equity infusion significantly bolsters the balance sheet and liquidity, supporting capital expenditure for API forward integration and capacity doubling, though it entails equity dilution.
Total fundraise value: Rs ~750 crShares to be allotted: 2,11,86,440Issue price: Rs 354 per shareFloor price: Rs 372.57 per shareIssue discount: 4.98%
📅 Short termAllotment and listing of 2.12 crore new shares will expand the institutional shareholder base and trading float.
📈 Long termSubstantial capital inflow provides full funding visibility for planned fermentation capacity expansion to 432 MT and forward integration into high-value APIs.
⚠ Risk flags
- Equity dilution for existing shareholders due to issuance of 2.12 crore new shares.
- High customer concentration risk remains (top 2 clients historically account for ~98% of sales).
Key Highlights
QIP issue closed on August 28, 2026 following receipt of institutional funds and applications.
Approved allotment of 2,11,86,440 equity shares of face value Rs 1 each.
Issue price fixed at Rs 354 per share, implying a total capital raise of ~Rs 750 crore.
Issue price is at a 4.98% discount (Rs 18.57 per share) to the floor price of Rs 372.57 per share.
👀 What to Watch
Track the formal allotment and listing of the new shares, along with management updates on deployment of the ~Rs 750 crore proceeds towards ongoing fermentation capacity expansion (doubling from 216 MT to 432 MT).
Gujarat Themis Biosyn Opens QIP; Sets Floor Price at ₹372.57 Per Share
Gujarat Themis Biosyn Limited approved the opening of its Qualified Institutions Placement (QIP) on August 25, 2026. The board set the SEBI ICDR floor price at ₹372.57 per equity share (face value ₹1 each), representing a 9.3% discount to the recent market price of ₹410.90. The company may, at its discretion, offer a discount of up to 5% on the floor price. The issue follows shareholder approval granted via a special resolution on August 22, 2026.
Confidence: HIGH
What changedGujarat Themis Biosyn has officially launched its QIP equity fundraise with a floor price of ₹372.57 per share.
Why it mattersThe fundraise will bring fresh institutional equity capital to support the company's business plans (including its ongoing capacity expansion to 432 MT), accompanied by equity dilution for existing shareholders.
Floor Price: ₹ 372.57 per shareShare Face Value: ₹ 1Max Permissible Discount: 5%Relevant Date: 25th August, 2026
📅 Short termStock price may adjust towards the placement price as the book-building process concludes and final allocations are made.
📈 Long termCapital raised strengthens the balance sheet to fund ongoing fermentation capacity doubling and API forward integration projects.
⚠ Risk flags
- Equity dilution for existing public shareholders
- Capital deployment and execution timeline risk on new projects
Key Highlights
QIP issue opened on August 25, 2026, following board and shareholder approvals.
SEBI ICDR floor price determined at ₹372.57 per equity share of face value ₹1.
Discretionary discount of up to 5% allowed on the determined floor price.
Relevant date for the pricing formula fixed as August 25, 2026.
👀 What to Watch
Track subsequent filings for the final issue price, total funds raised, and the list of institutional allottees upon QIP closure.
Gujarat Themis Biosyn Shareholders Approve QIP and NCD Fundraise via Postal Ballot
Gujarat Themis Biosyn Limited has announced the successful passing of three special resolutions via postal ballot e-voting. Shareholders approved enabling resolutions to raise funds through a Qualified Institutions Placement (QIP) of equity shares and via private placement of Non-Convertible Debentures (NCDs) / debt securities. The QIP resolution received 99.97% votes in favor (77,845,234 votes), while the NCD resolution received 99.97% approval (77,844,780 votes). Total voting turnout stood at 71.46% of outstanding shares.
Confidence: HIGH
What changedShareholders formally approved enabling resolutions to raise capital through QIP and debt instruments.
Why it mattersProvides management with the enabling authority to raise external capital to support ongoing capex and capacity expansion programs.
Total shares outstanding: 108965265Total votes polled: 77865914Voter turnout: 71.4594%QIP approval rate: 99.9734%NCD approval rate: 99.9729%
📅 Short termClearance of enabling resolutions positions the company to launch a fundraise depending on market conditions.
📈 Long termSecuring equity or debt financing will provide headroom for planned growth initiatives, including fermentation capacity expansion and API integration.
⚠ Risk flags
- Potential equity dilution risk if and when the QIP is executed
Key Highlights
Resolution for equity fundraise via Qualified Institutions Placement (QIP) approved with 99.9734% votes in favour.
Private placement of NCDs and debt securities approved with 99.9729% votes in favour.
Amendment to the Articles of Association approved with 99.9969% votes in favour.
Total voter participation was 71.4594%, with 77,865,914 votes polled across 108,965,265 total shares.
👀 What to Watch
Track future board disclosures regarding the exact quantum, floor price, and timing of any upcoming QIP or debt issuance.
Q1 PAT Rises 22% to ₹11.1 Cr; Management Outlines ₹3,000 Cr Global Acquisition Roadmap
Gujarat Themis Biosyn reported a 22.1% YoY increase in Q1 FY27 revenue to ₹43.8 crore, driven by robust volume growth. EBITDA rose 49.4% YoY to ₹20.8 crore with margins expanding 867 bps to 47.5%, while PAT grew 22.1% YoY to ₹11.1 crore. Management detailed its transformational M&A strategy, including the acquisition of MicroBiopharm Japan for precision fermentation capabilities and 13 global anti-TB/anti-infective brands from Sanofi across 55 countries. Addressing financing of the estimated ₹3,000 crore acquisition outlay, management highlighted that foreign debt costs will be significantly lower than Indian rates and expected the assets to be cash flow positive.
Confidence: HIGH
What changedGujarat Themis published its Q1 FY27 earnings transcript detailing operational performance and execution plans for its large-scale overseas acquisitions.
Why it mattersThe company is transitioning from a localized intermediate manufacturer into an integrated, global fermentation-based CDMO player with branded formulations in 55 export markets.
Q1 FY27 Revenue: ₹43.8 crQ1 FY27 EBITDA Margin: 47.5%Q1 FY27 PAT: ₹11.1 crSanofi Acquired Brands: 13 brandsSanofi Geographic Reach: 55 countries
📅 Short termOperational momentum is solid with EBITDA margins at 47.5%, while market focus will remain on the execution and fundraise structuring for the announced overseas deals.
📈 Long termIf successfully integrated, the twin acquisitions of MicroBiopharm Japan and Sanofi's brand portfolio will exponentially scale revenue from the historic ₹150-180 crore annual run rate to over ₹1,000 crore.
⚠ Risk flags
- High leverage and equity dilution risk related to proposed ₹2,000 cr debt and ₹1,000 cr QIP
- Long regulatory approval gestation (long stop date June next year) across 50+ jurisdictions for the Sanofi transaction
- Customer and supply chain concentration risks during the ongoing integration phase
Key Highlights
Q1 FY27 revenue grew 22.1% YoY to ₹43.8 crore from ₹35.9 crore in Q1 FY26
EBITDA increased 49.4% YoY to ₹20.8 crore, expanding EBITDA margins by 867 bps to 47.5%
PAT increased 22.1% YoY to ₹11.1 crore compared to ₹9.1 crore in the year-ago period
Acquiring 13 anti-TB and anti-infective brands from Sanofi covering 55 countries across EMEA, with closing targeted before June next year
Acquiring MicroBiopharm Japan to add advanced capabilities in ADCs, plasmids, peptides, and enzyme engineering
👀 What to Watch
Track the closing timeline of the MicroBiopharm Japan deal and regulatory approvals across 55 countries for the Sanofi asset carve-out, along with the pricing and dilution terms of the proposed ₹1,000 crore QIP.
GUJTHEM Q1 PAT up 22%; Announces ~INR 1,300 Cr Japan Acquisition & EUR 158 Mn Sanofi Deal
Gujarat Themis Biosyn (GUJTHEM) reported a strong Q1 FY27 with revenue of Rs 43.8 Cr (+22.1% YoY) and EBITDA margins expanding 867 bps to 47.5%. The company announced two massive, transformative acquisitions: MicroBiopharm Japan for ~INR 1,300 Cr and a Sanofi brand portfolio for ~EUR 158 Mn. These deals are highly material, collectively exceeding 15x the company's FY26 revenue of Rs 165.8 Cr. The company has also completed its fermentation capacity doubling to 432 MT and is commissioning an 18 MW hybrid power plant to optimize costs.
Confidence: HIGH
What changedGUJTHEM is pivoting from a small-scale intermediate manufacturer to a global CDMO player through two massive international acquisitions and a doubling of its domestic fermentation capacity.
Why it mattersThe acquisitions provide immediate global market access and high-value technology (peptides, oncology), potentially re-rating the business by diversifying its revenue base and moving it up the value chain into APIs and finished dosages.
MicroBiopharm Deal Value: ~INR 1,300 CrSanofi Portfolio Deal Value: ~EUR 158 MnQ1 FY27 EBITDA Margin: 47.48%New Fermentation Capacity: 432 MTQ1 FY27 Revenue: Rs 43.8 CrHybrid Power Capacity: 18 MW
📅 Short termPositive sentiment is expected due to the scale of inorganic growth announcements and strong margin expansion in Q1 results.
📈 Long termStructural transformation into a global CDMO; long-term success depends on the successful integration of Japanese and European assets and managing the debt taken for these acquisitions.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk of large international acquisitions
- High client concentration (98% revenue from top 2 clients)
- Potential balance sheet leverage from ~INR 2,700 Cr+ total acquisition cost
Key Highlights
Acquisition of MicroBiopharm Japan for JPY 21.5 Bn (~INR 1,300 Cr), adding ~INR 575 Cr in revenue.
Acquisition of 13 Sanofi brands for ~EUR 158 Mn, covering 55+ countries in TB and anti-infectives.
Q1 FY27 EBITDA grew 49.4% YoY to Rs 20.8 Cr, driven by volume-led economies of scale.
Fermentation capacity expansion from 216 MT to 432 MT is now complete.
18 MW Hybrid wind-solar power project underway to reduce grid dependence and power costs.
👀 What to Watch
Monitor the regulatory approval timeline for the MicroBiopharm acquisition (expected Q2 FY27) and the funding structure (debt/equity mix) for these large-scale deals. Watch for the integration of Sanofi's brands and their impact on reducing the current 98% revenue concentration from two major clients.
GUJTHEM Q1 FY27 PAT Up 22% YoY to ₹11.07 Cr; Revenue Reaches ₹43.79 Cr
Gujarat Themis Biosyn reported a steady Q1 FY27 with standalone revenue growing 22% YoY to ₹43.79 Cr, up from ₹35.87 Cr in Q1 FY26. Net profit followed a similar trajectory, rising 22% YoY to ₹11.07 Cr. The company maintained robust profitability with a Profit Before Tax (PBT) margin of 34.5%. Consolidated results show that newly formed subsidiaries in Japan and Ireland are currently non-operational, contributing nil to the top line.
Confidence: HIGH
What changedThe company has reported its Q1 FY27 financial results, showing sustained YoY growth in both revenue and profitability following the commercialization of new APIs in mid-2025.
Why it mattersThe results confirm the successful stabilization of new fermentation-based APIs (Rifapentine and Rifamycin) and demonstrate the company's ability to maintain high margins despite rising employee and power costs.
Revenue (Q1 FY27): ₹43.79 CrNet Profit (Q1 FY27): ₹11.07 CrYoY Revenue Growth: 22.07%PBT Margin: 34.5%EPS: ₹1.02
📅 Short termThe stock may react positively to the double-digit YoY growth in earnings and the maintenance of healthy operating margins.
📈 Long termLong-term value depends on the successful doubling of capacity to 432 MT and the operationalization of international subsidiaries to diversify revenue streams.
⚠ Risk flags
- Extreme client concentration (98% of revenue from two clients)
- Non-operational status of foreign subsidiaries
- High dependency on fermentation-based intermediates which face Chinese competition
Key Highlights
Revenue from operations increased 22.07% YoY to ₹43.79 Cr.
Net Profit (PAT) rose to ₹11.07 Cr compared to ₹9.06 Cr in the year-ago quarter.
Profit Before Tax (PBT) stood at ₹15.17 Cr, representing a 34.5% margin on total income.
Earnings Per Share (EPS) improved to ₹1.02 from ₹0.83 in Q1 FY26.
Total expenses increased to ₹28.76 Cr, with raw material costs accounting for ₹7.73 Cr.
👀 What to Watch
Investors should monitor the execution of the fermentation capacity doubling (from 216 MT to 432 MT) expected by the end of FY26 and track if the high client concentration (98% from two clients) begins to diversify with new API launches.
₹1500 Cr Debt Fundraise Limit and Promoter Debt-to-Equity Conversion Proposed
Gujarat Themis Biosyn (GUJTHEM) has convened an EGM on August 22, 2026, to seek shareholder approval for a massive ₹1500 Cr debt fundraise limit via NCDs. This proposed limit is approximately 38.6x its FY24 revenue of ₹38.86 Cr, signaling a potential for significant inorganic growth or massive capital expenditure. Additionally, the company is seeking approval for material related party transactions with promoters, including a provision to convert outstanding borrowings into equity shares. An amendment to the Articles of Association is also proposed to simplify the process for further issuance of share capital.
Confidence: HIGH
What changedThe company is moving from a small-scale operation (₹38.86 Cr revenue) to creating a massive capital buffer (₹1500 Cr) and enabling flexible equity issuance mechanisms.
Why it mattersThe scale of the proposed fundraise is disproportionately large compared to the current business size, suggesting a major strategic shift or M&A. The debt-to-equity conversion provides a path for promoters to increase or maintain stakes while funding the company.
Proposed Debt Limit: ₹1500 CrDebt Limit vs FY24 Revenue: 38.6xFY24 Revenue: ₹38.86 CrPromoter Holding: 70.86%Current Capacity: 216 MTEGM Date: August 22, 2026
📅 Short termThe stock may see volatility as the market digests the magnitude of the ₹1500 Cr fundraise and the implications of the debt-to-equity conversion.
📈 Long termIf the capital is deployed effectively for the 100% capacity expansion or M&A, it could structurally re-rate the company; however, the high client concentration (98% from two clients) remains a structural risk.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Potential equity dilution from debt-to-equity conversion
- High debt-to-revenue ratio if limit is fully utilized
- Extreme client concentration (98% of sales to 2 clients)
Key Highlights
Proposed issuance of Non-Convertible Debentures (NCDs) and debt securities up to a principal amount of ₹1500 Crores.
Provision to convert promoter borrowings from Pharmaceutical Business Group India Ltd and Dr. Sachin Patel into equity shares.
Amendment to Article 13 of the Articles of Association to remove the mandatory 'registered valuer' wording for specific share issuances.
EGM scheduled for August 22, 2026, to vote on these special and ordinary resolutions.
Company is currently doubling fermentation capacity from 216 MT to 432 MT, targeted for completion by FY26.
👀 What to Watch
Investors should closely monitor the EGM results and subsequent board announcements regarding the specific utilization of the ₹1500 Cr debt limit. The potential for equity dilution through the debt-to-equity conversion clause for promoters is a critical factor to watch.
47.02% stake in Gujarat Themis Biosyn indirectly encumbered via promoter pledge
CTL Trusteeship has disclosed an indirect encumbrance on 5,12,40,000 shares of Gujarat Themis Biosyn Limited (GUJTHEM), representing 47.02% of its total capital. This encumbrance arises from a pledge and non-disposal undertaking (NDU) created by Vividhmargi Investments Private Limited (VIPL) over its 98.988% stake in Pharmaceutical Business Group (India) Limited (PBGIL), the primary promoter entity. The action secures debentures issued by OSS Software Solutions Labs Private Limited under a deed dated June 25, 2026. Effectively, nearly the entire promoter-level holding in the company is now indirectly encumbered to secure third-party debt.
Confidence: HIGH
What changedA significant portion of the promoter's indirect holding in GUJTHEM has been pledged and placed under a non-disposal undertaking to secure debentures issued by a third party.
Why it mattersHigh promoter-level leverage is a risk factor; if the underlying debt is not serviced, it could lead to forced liquidation of the promoter's stake or a change in control.
Indirectly encumbered stake: 47.02%Shares held by PBGIL: 5,12,40,000VIPL stake in PBGIL: 98.988%Pledge effective date: June 29, 2026
📅 Short termNeutral to cautious; the market may react to the high level of indirect promoter pledge as it introduces a layer of financial risk.
📈 Long termStructural risk exists regarding promoter stability and potential ownership shifts if the holding company debt is not managed.
⚠ Risk flags
- High indirect promoter pledge (47.02%)
- Potential for forced liquidation if debentures default
- Third-party debt security
Key Highlights
Indirect encumbrance created on 5,12,40,000 equity shares of the Target Company
Encumbrance covers 47.02% of the total issued and paid-up share capital of GUJTHEM
Vividhmargi Investments pledged 51% and placed 47.988% under NDU in the promoter entity PBGIL
The arrangement secures debentures issued by OSS Software Solutions Labs Private Limited effective June 29, 2026
👀 What to Watch
Monitor the financial health of the issuer (OSS Software Solutions Labs) and any further disclosures regarding the purpose of this leverage. High promoter-level encumbrance can increase stock volatility during market downturns.
GUJTHEM Seeks Shareholder Approval for Fundraise via QIP to Support Expansion
Gujarat Themis Biosyn (GUJTHEM) has issued a postal ballot notice to seek shareholder approval for raising funds through a Qualified Institutions Placement (QIP). This resolution supersedes a previous special resolution passed on July 8, 2026. The fundraising is likely intended to support the company's ongoing 100% capacity expansion from 216 MT to 432 MT. The e-voting period is scheduled from July 24 to August 22, 2026, with results expected by August 25, 2026.
Confidence: HIGH
What changedThe company is seeking fresh shareholder approval for a QIP, superseding a resolution passed earlier in July 2026, indicating a formalization of its capital-raising plans.
Why it mattersThe fundraise is critical for GUJTHEM's strategy to scale from a small-cap intermediate manufacturer to a larger API player, aiming for a nearly 6x increase in revenue compared to FY24 levels.
FY24 Revenue: ₹38.86 CrTarget Operating Income: >₹250 CrCapacity Expansion: 100% (216 MT to 432 MT)Voting End Date: August 22, 2026Results Declaration Date: August 25, 2026
📅 Short termThe stock may see increased interest as institutional participation via QIP often signals confidence in the company's growth trajectory.
📈 Long termSuccess depends on the timely execution of the 432 MT capacity expansion and reducing the 98% revenue concentration from its top two clients.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Equity dilution for existing shareholders
- High client concentration (98% of revenue from Lupin and Optrix)
- Execution risk in doubling capacity by FY26
Key Highlights
Proposed fundraise via QIP to issue equity shares of face value ₹1 each.
E-voting period commences on July 24, 2026, and ends on August 22, 2026.
Company is doubling fermentation capacity from 216 MT to 432 MT by FY26.
Targeting total operating income exceeding ₹250 Cr, a significant jump from FY24 revenue of ₹38.86 Cr.
Cut-off date for voting eligibility was set as July 10, 2026.
👀 What to Watch
Monitor the outcome of the postal ballot on August 25, 2026, and watch for subsequent disclosures regarding the QIP size and floor price to assess potential equity dilution.
₹3,000 Cr Acquisitions Trigger CARE Rating Watch with Negative Implications
CARE Ratings has placed Gujarat Themis Biosyn (GTBL) on 'Rating Watch with Negative Implications' following the announcement of two massive acquisitions totaling approximately ₹3,000 crore. The company plans to acquire MicroBiopharm Japan for ~₹1,300 crore and a Sanofi anti-TB portfolio for ~₹1,700 crore, a combined outlay representing 10x the company's tangible net worth. While GTBL plans to fund this partly through a ₹1,000 crore QIP, the rating agency cited concerns over funding uncertainty and high leverage. The company has formally dissented, arguing that the acquisitions will be EBITDA-accretive and that QIP roadshows are already in progress.
Confidence: HIGH
What changedThe company's credit rating outlook was moved from stable to 'Rating Watch with Negative Implications' due to the financial risks of two transformative acquisitions.
Why it mattersThe acquisitions are massive relative to the company's current size (10x net worth) and could either exponentially scale the business or severely strain the balance sheet if the ₹1,000 crore fundraise or integration fails.
Total Acquisition Value: ₹3,000 crorePlanned QIP Size: ₹1,000 croreAcquisition vs Net Worth: ~10xNet Debt/EBITDA: 2.25Target Operating Income: >₹250 crore
📅 Short termThe 'Negative Watch' may cause short-term price volatility as the market assesses the risk of equity dilution from the QIP and the high debt requirements.
📈 Long termIf successfully integrated, these acquisitions could transform GTBL from a niche intermediate manufacturer into a global API and brand player, though execution risk is high.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High leverage (10x net worth acquisition)
- Funding uncertainty for the ₹3,000 cr outlay
- Extreme customer concentration (98% revenue from 2 clients)
- Execution risk in global M&A
Key Highlights
Acquisition of MicroBiopharm Japan Co., Ltd. for ¥1.5 Billion (~₹1,300 crore) expected by Q2FY27.
Asset purchase agreement with Sanofi for anti-TB and anti-infective brands for €158 million (~₹1,700 crore).
Total acquisition value is approximately 10 times the company's current tangible net worth.
Planned ₹1,000 crore Qualified Institutional Placement (QIP) to manage the funding mix.
Current Net Debt/EBITDA stands at 2.25, with potential for significant increase depending on final funding structure.
👀 What to Watch
Monitor the successful execution and pricing of the ₹1,000 crore QIP, as it is critical for the acquisition timeline. Investors should also track regulatory approvals for the Japanese and Sanofi transactions and the subsequent impact on the debt-to-equity ratio.
CARE places GUJTHEM on Negative Watch following ₹3,000 Cr Acquisition Plans
CARE Ratings has placed Gujarat Themis Biosyn's 'BBB' rating on 'Rating Watch with Negative Implications' due to two massive proposed acquisitions totaling approximately ₹3,000 crore. These include the acquisition of MicroBiopharm Japan for ~₹1,300 crore and a Sanofi anti-TB portfolio for ~₹1,700 crore, which together represent over 10x the company's tangible net worth of ₹287.67 crore. The company plans to fund these via a ₹1,000 crore QIP and other yet-to-be-finalized structures. Management has formally dissented against this rating action, citing that it ignores structural de-risking and future cash flow additions.
Confidence: HIGH
What changedCARE Ratings has moved the company's credit rating from a stable outlook to 'Rating Watch with Negative Implications' following the announcement of massive global acquisitions.
Why it mattersThe acquisitions are transformative in scale but carry extreme financial risk as they are 10 times the company's current net worth. The rating watch reflects uncertainty regarding the funding structure and potential leverage deterioration.
Total Acquisition Value: ~₹3,000 croreAcquisition vs Net Worth: 1042%Proposed QIP Size: ₹1,000 croreTangible Net Worth (Mar 2026): ₹287.67 croreOverall Gearing (FY26): 0.56x
📅 Short termThe rating watch and the company's formal dissent may lead to short-term price volatility as the market assesses the funding risk of the ₹3,000 crore deals.
📈 Long termIf successfully integrated and funded without excessive dilution or debt, these acquisitions could exponentially scale the business; however, execution and integration risks are currently very high.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Extreme leverage risk (acquisitions 10x net worth)
- Funding uncertainty (QIP dependency)
- High customer concentration (98% revenue from 2 clients)
- International integration risk
Key Highlights
Proposed acquisition of MicroBiopharm Japan (MBJ) for ~₹1,300 crore (¥1.5 Billion) expected by Q2FY27.
Asset purchase agreement with Sanofi for anti-TB brands valued at ~₹1,700 crore (€158 million).
Total acquisition outlay of ~₹3,000 crore is roughly 10.4x the company's March 2026 net worth of ₹287.67 crore.
Company planning a ₹1,000 crore Qualified Institutional Placement (QIP) to fund the MBJ acquisition.
Overall gearing moderated to 0.56x as of March 31, 2026, compared to 0.12x in the previous year due to capex loans.
👀 What to Watch
Investors should closely monitor the successful completion of the ₹1,000 crore QIP and regulatory approvals for the Japanese and Sanofi acquisitions. The key risk to watch is the final debt-equity mix and the company's ability to service significantly higher debt levels post-acquisition.
47.02% Indirect Promoter Stake Encumbered via Pledge and Non-Disposal Undertaking
Pharmaceutical Business Group (India) Limited (PBGIL), a promoter entity holding 47.02% of Gujarat Themis Biosyn Limited (GTBL), has seen its entire holding indirectly encumbered. This resulted from Vividhmargi Investments Private Limited (VIPL) pledging 51% and entering a non-disposal undertaking for 47.98% of PBGIL's shares in favor of CTL Trusteeship Limited. The transaction is linked to a Debenture Trust Deed dated June 25, 2026. While the pledge is at the holding company level, it effectively places a lien on the majority of the promoter's interest in GTBL.
Confidence: HIGH
What changedA promoter-level holding company (VIPL) has encumbered its entire stake in the direct promoter (PBGIL), creating an indirect lien on GTBL's shares.
Why it mattersHigh promoter pledging is a significant risk factor as it can lead to forced selling or a change in control if the underlying debt obligations are not met, potentially causing high stock price volatility.
Total shares encumbered: 5,12,40,000% of GTBL equity: 47.02%Pledge in PBGIL: 51%NDU in PBGIL: 47.98%Date of creation: 29/06/2026
📅 Short termThe stock may face some pressure or volatility as the market reacts to the high level of indirect promoter pledging.
📈 Long termWhile the company is expanding capacity to 432 MT by FY26, the promoter-level debt adds a layer of structural risk that must be balanced against growth prospects.
⚠ Risk flags
- High promoter pledging (indirectly 47.02% of the company)
- Extreme client concentration (98% of revenue from two clients)
- Promoter-level debt obligations
Key Highlights
Indirect encumbrance created on 5,12,40,000 equity shares of GTBL
The encumbered stake represents 47.02% of the total issued and paid-up share capital
Pledge involves 25,24,245 shares (51%) and non-disposal undertaking involves 21,57,855 shares (47.98%) of the promoter entity PBGIL
Action taken in favor of CTL Trusteeship Limited pursuant to a Debenture Trust Deed dated June 25, 2026
The encumbrance was officially created on June 29, 2026
👀 What to Watch
Investors should monitor for any further disclosures regarding the purpose of the debt raised at the promoter level and watch for any signs of financial stress that could lead to an invocation of the pledge.
Shareholders Approve Fundraise via QIP with 99.97% Majority
Gujarat Themis Biosyn Limited (GUJTHEM) has received shareholder approval to raise funds through a Qualified Institutions Placement (QIP). The special resolution was passed with an overwhelming 99.9762% majority of the 7.94 crore votes polled. This capital raise is intended to support the company's strategic growth plan, which includes doubling fermentation capacity from 216 MT to 432 MT by FY26 and expanding into higher-value APIs. While the specific fundraise amount was not disclosed in this filing, the mandate allows the board to proceed with the capital infusion.
Confidence: HIGH
What changedShareholders have officially authorized the company to raise capital through a QIP, providing the board with a formal mandate to issue new equity shares to institutional investors.
Why it mattersThis fundraise is critical for financing the company's expansion strategy, which aims to increase total operating income to over INR 250 Cr (a 66% increase) and reduce reliance on a narrow product range through forward integration into APIs like Rifapentine.
Votes in favor (%): 99.9762%Total votes polled: 7,94,96,307Promoter votes in favor: 7,65,57,741Target capacity expansion: 432 MTTarget Operating Income: >INR 250 Cr
📅 Short termThe stock may see positive sentiment as the shareholder approval clears a major regulatory hurdle for the company's growth financing.
📈 Long termSuccessful capital raising and subsequent capacity doubling to 432 MT by FY26 could structurally re-rate the business, provided it manages its high client concentration (98% revenue from two clients).
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Equity dilution for existing shareholders
- High client concentration (Lupin and Optrix account for 98% of sales)
- Execution risk in doubling fermentation capacity by FY26
Key Highlights
99.9762% of total votes cast in favor of the QIP fundraise resolution
100% support from the Promoter and Promoter Group with 7,65,57,741 votes in favor
98.5444% support from Public Institutions for the special resolution
Total of 7,94,96,307 votes polled across all shareholder categories
Resolution passed via Postal Ballot through e-voting as per the notice dated June 6, 2026
👀 What to Watch
Investors should monitor subsequent filings for the specific QIP floor price and the total quantum of capital to be raised. The key execution milestone to watch is the deployment of these funds toward the 100% fermentation capacity expansion scheduled for completion by FY26.
Shareholders Approve Fundraise via Qualified Institutions Placement (QIP)
Shareholders of Gujarat Themis Biosyn have approved a special resolution to raise capital through a Qualified Institutions Placement (QIP). The resolution received overwhelming support with 99.97% of votes cast in favor. This capital raise is intended to support the company's strategic goal of doubling fermentation capacity from 216 MT to 432 MT by FY26. While the specific fundraise amount was not disclosed in this filing, the approval is a critical step for financing its expansion into higher-value APIs.
Confidence: HIGH
What changedShareholders have officially authorized the board to issue equity shares to institutional investors, clearing the path for a QIP fundraise.
Why it mattersThis provides the financial means to execute a 100% capacity expansion and forward integration into APIs like Rifapentine, which are central to the company's growth strategy.
Votes in favor: 99.9762%Total votes polled: 7,94,96,307Target capacity expansion: 432 MTCurrent capacity: 216 MT
📅 Short termThe approval removes regulatory uncertainty regarding the company's ability to raise capital, which may be viewed positively by the market in the coming weeks.
📈 Long termThe fundraise is structurally significant as it fuels the doubling of production capacity and entry into higher-margin API segments by FY26.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Equity dilution for existing shareholders
- High customer concentration (98% revenue from 2 clients)
Key Highlights
99.9762% of total votes cast were in favor of the QIP fundraise resolution
Promoter group cast 7,65,57,741 votes, all 100% in favor of the resolution
Total of 7,94,96,307 votes were polled during the postal ballot process
The fundraise supports the company's target to exceed INR 250 Cr in Total Operating Income
Capacity expansion from 216 MT to 432 MT is expected to be operational by end of FY26
👀 What to Watch
Investors should monitor subsequent filings for the specific QIP floor price and the total quantum of funds to be raised. The execution timeline of the fermentation capacity doubling will be the primary driver of long-term value.
99.98% Shareholder Approval for Fundraise via Qualified Institutions Placement (QIP)
Shareholders of Gujarat Themis Biosyn have approved a special resolution to raise funds through a Qualified Institutions Placement (QIP). The proposal received overwhelming support with 99.9762% of votes cast in favor, representing 72.96% of the total share capital. This capital raise is intended to support the company's strategic goal of doubling fermentation capacity from 216 MT to 432 MT by FY26. While the specific fundraise amount was not disclosed in this voting report, the approval is a critical step for the company's expansion into higher-value APIs.
Confidence: HIGH
What changedShareholders have officially authorized the company to raise capital through a QIP, clearing the regulatory path for institutional fund infusion.
Why it mattersThe fundraise is essential for financing the company's 100% capacity expansion and its transition into a higher-value API manufacturer, aiming for a revenue target exceeding Rs 250 Cr.
Votes in favor: 99.9762%Total shares: 108,965,265Voter turnout: 72.9556%Promoter support: 100%Planned capacity expansion: 100% (to 432 MT)
📅 Short termPositive sentiment expected as the company secures shareholder backing for growth capital; focus will now shift to institutional demand and pricing of the QIP.
📈 Long termStructurally significant if the capital is used to successfully double capacity and diversify the product mix, potentially reducing the current 98% revenue concentration from two clients.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Equity dilution for existing shareholders
- High client concentration (98% revenue from two clients)
- Execution risk in doubling fermentation capacity
Key Highlights
Special resolution for QIP fundraise passed with 99.9762% majority in favor
Total of 79,477,366 votes cast in favor of the resolution out of 79,496,307 polled
Promoter group holding 77,218,083 shares voted 100% in favor of the proposal
Overall voter turnout stood at 72.9556% of the total 108,965,265 shares
Fundraise supports the planned 100% capacity expansion to 432 MT by FY26
👀 What to Watch
Monitor upcoming board announcements regarding the QIP floor price and the total quantum of funds to be raised. Track the deployment of these funds toward the fermentation capacity expansion and the stabilization of the new API unit.
99.98% Shareholder Approval for Fundraise via QIP
Gujarat Themis Biosyn Limited (GUJTHEM) has received overwhelming shareholder approval to raise funds through a Qualified Institutions Placement (QIP). The special resolution saw 99.9762% of the 7.95 crore votes cast in favor, including 100% support from the promoter group. This capital infusion is intended to support the company's strategic goal of doubling its fermentation capacity from 216 MT to 432 MT by FY26. The approval marks a critical step in financing the company's transition into higher-value APIs like Rifapentine.
Confidence: HIGH
What changedShareholders have officially authorized the company to raise capital through a QIP, transitioning the proposal into an actionable corporate event.
Why it mattersThis fundraise is essential for GUJTHEM to achieve its target of doubling capacity and reaching a Total Operating Income exceeding INR 250 Cr. It provides the financial runway for forward integration into the API market, reducing reliance on intermediates.
Approval Percentage: 99.9762%Total Votes Polled: 7,94,96,307Promoter Votes in Favor: 7,65,57,741Target Capacity Expansion: 432 MTCurrent Capacity: 216 MT
📅 Short termThe successful vote is likely to be viewed positively by the market as it clears the path for capital infusion; focus will now shift to the QIP pricing and participant list.
📈 Long termThe fundraise is structurally significant as it facilitates a 100% capacity increase and diversification into higher-margin APIs, which are expected to drive the next phase of revenue growth.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Equity dilution for existing retail shareholders
- High client concentration (98% of revenue from two clients)
- Execution risk associated with doubling fermentation capacity
Key Highlights
99.9762% of total votes (7,94,77,366 votes) were cast in favor of the QIP fundraise resolution.
Promoter group, holding 7.72 crore shares, voted 100% in favor of the proposal.
Public institutional investors showed 98.54% support with 12.61 lakh votes in favor.
The fundraise supports the planned 100% capacity expansion from 216 MT to 432 MT.
Total votes polled represented 72.95% of the total 10.89 crore outstanding shares.
👀 What to Watch
Investors should monitor subsequent board announcements regarding the specific QIP floor price and the total quantum of capital to be raised. The execution timeline for the 432 MT capacity expansion remains the primary long-term performance indicator.
GUJTHEM to Acquire Sanofi Portfolio for €158M and MicroBiopharm Japan (INR 561 Cr Revenue)
Gujarat Themis Biosyn (GTBL) has announced two transformative acquisitions: Sanofi’s anti-TB portfolio for €158 million and MicroBiopharm Japan (MBJ) with FY26 revenues of JPY 9.5 Bn (~INR 561.82 Cr). These acquisitions represent a massive scale-up, as the combined target revenues are approximately 6.7x GTBL's FY26 revenue of INR 165.82 Cr. Additionally, the company has doubled its fermentation capacity to 990 KL in FY26 and completed forward integration into APIs. While growth prospects are significant, the €158 million deal value is nearly 4.8x the company's FY26 net worth of INR 287.77 Cr, indicating a major funding requirement.
Confidence: HIGH
What changedGTBL is transitioning from a domestic fermentation intermediate manufacturer into a global CDMO and branded pharmaceutical platform through two large-scale international acquisitions.
Why it mattersThe acquisitions provide immediate access to regulated markets (Europe, Japan) and high-value therapeutic areas like oncology and biologics, potentially re-rating the company from a small-cap supplier to a global player.
Sanofi Portfolio Deal Value: €158 millionMBJ FY26 Revenue: INR 561.82 CrGTBL FY26 Revenue: INR 165.82 CrCombined Target Revenue vs GTBL FY26: ~670%Sanofi Deal vs FY26 Net Worth: ~486%Installed Fermentation Capacity: 990 KL
📅 Short termThe market is likely to react positively to the massive expansion in scale and global footprint, though details on funding the €158m acquisition will be a key focus.
📈 Long termIf successfully integrated, these acquisitions structurally transform GTBL into a diversified global pharma entity with proprietary technology in fermentation and biologics.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Significant funding requirement for €158m deal relative to net worth
- High execution risk in integrating Japanese and European operations
- Current high customer concentration (98% of revenue from two clients)
Key Highlights
Acquisition of Sanofi's 13 anti-TB and anti-infective brands for €158 million, covering 59 countries
Acquisition of MicroBiopharm Japan (MBJ) adding JPY 9.5 Bn (~INR 561.82 Cr) in revenue and 3 manufacturing plants
Annual fermentation capacity increased by 120% from 450 KL in FY25 to 990 KL in FY26
Maintained high operational efficiency with an EBITDA margin of 45.55% on FY26 revenue of INR 165.82 Cr
Forward integration completed for Rifapentine and Rifamycin APIs, moving up the value chain from intermediates
👀 What to Watch
Monitor the regulatory approval timeline for both acquisitions and the specific financing structure (debt vs. equity) for the €158 million Sanofi deal. Watch for the successful integration of MBJ's advanced biotech capabilities like ADCs and Plasmids into GTBL's existing fermentation platform.
Gujarat Themis Biosyn Initiates ₹90.24 Crore Arbitration Against Optimus Drugs
Gujarat Themis Biosyn Limited (GTBL) has initiated arbitration proceedings against Optimus Drugs Private Limited for the wrongful termination of a supply agreement. The company is seeking a total recovery of approximately ₹90.24 crores, primarily driven by a ₹75 crore claim for breach of 'Take-or-Pay' obligations. Additionally, the company is claiming ₹15 crores in damages and ₹23.81 lakhs for interest on delayed payments. As GTBL is the claimant, the management does not expect any negative financial implications or penalties from this proceeding.
Key Highlights
Initiated arbitration against Optimus Drugs Private Limited for breach of contract terms.
Claiming ₹75.00 crore in break fees due to violation of mandatory 'Take-or-Pay' purchase obligations.
Seeking ₹15.00 crore towards general damages and financial losses resulting from the termination.
Additional claim of ₹23.81 lakh for interest on delayed payments plus ongoing interest.
Management confirms no expected financial liability as the company is the party seeking recovery.
👀 What to Watch
Investors should view this as a potential long-term cash flow catalyst, though arbitration outcomes can take significant time to materialize. Monitor future disclosures for the tribunal's interim orders or final settlement terms.
